⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SNDX News
Syndax Pharmaceuticals, Inc.
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
globenewswire.com
SNDX
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
globenewswire.com
SNDX
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
globenewswire.com
SNDX
Syndax Announces Participation in Upcoming Investor Conferences
globenewswire.com
SNDX
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
globenewswire.com
SNDX
Ligand Reports First Quarter 2026 Financial Results
globenewswire.com
LGND
XOMA
MRK
SNDX
AGEN
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
SNDX
Form 8-K
sec.gov
SNDX
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
SNDX
Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
globenewswire.com
SNDX